Abstract：Objective To explore the antiventricular arrhythmia effect of sacubitril/valsartan (LCZ696) on patients with chronic heart failure. Methods We selected 116 heart failure patients with reduced ejection fraction (HFrEF) as the research subjects. Electrocardiogram (ECG) and ambulatory electrocardiography(AECG) results were made comparative analysis before taking LCZ696 and 6 months after treatment. ResultsThe utilization rate of drugs including betablockers, spironolactone, digoxin and amiodarone does not vary significantly before taking LCZ696 and 6 months after treatment (P>0.05). Compared with those before treatment, QRS duration [(124.8±35.2) ms vs. (120.7±32.7) ms] and SV1+RV5[(20.9±11.3) mm vs. (17.1±9.3) mm] after treatment both significantly decrease (P<0.05); corrected QT interval (QTc) [(461.6±40.2) ms vs. (448.5±39.5) ms] and QT dispersion (QTd)[(78.2±10.6) ms vs. (51.2±8.6) ms] after treatment both significantly decrease (P<0.01). The number of patients attacked by sustained ventricular tachycardia after treatment decreases from 8 to 3 (P<0.05); the total number of SVT attacks decreases from 19 to 5 (P<0.01). The number of cases attacked by non-sustained ventricular tachycardia (NSVT) decreases from 61 to 49 (P<0.01); the number of attacks of NSVT per person decreases from (7.2±9.8) to (3.5±4.9) (P<0.01); the number of attacks of premature ventricular contraction per hour is reduced from (35.0±6.2) times to (9.0±3.5) times (P<0.01). Conclusion LCZ696 therapy is associated with decreased risk of ventricular arrhythmia, and significantly reduced QRS duration, QTc and QTd among patients with heart failure.
裴强，王强，羊镇宇，陈茂华，王如兴. 沙库巴曲缬沙坦对慢性心力衰竭患者的抗室性心律失常作用[J]. 实用心电学杂志, 2021, 30(5): 342-345.
PEI Qiang, WANG Qiang, YANG Zhenyu, CHEN Maohua, WANG Ruxing. Anti-ventricular arrhythmia effect of sacubitril/valsartan on patients with chronic heart failure. JOURNAL OF PRACTICAL ELECTROCARDIOLOGY, 2021, 30(5): 342-345.
